Lilly's rheumatoid arthritis drug cuts COVID-19 deaths in trial, data shows – Reuters

Lilly’s rheumatoid arthritis drug cuts COVID-19 deaths in trial, data shows – Reuters

Eli Lilly and Co said on Thursday fewer deaths were reported among COVID-19 patients taking a combination of its rheumatoid arthritis drug and Gilead Sciences Inc’s remdesivir in a clinical trial, compared to only remdesivir.

Read More…

You May Also Like